Browse > Article
http://dx.doi.org/10.5483/BMBRep.2020.53.8.121

Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment  

Jayaramayya, Kaavya (Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University)
Mahalaxmi, Iyer (Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women)
Subramaniam, Mohana Devi (SN ONGC Department of Genetics and Molecular Biology, Vision Research Foundation, Sankara Nethralaya campus)
Raj, Neethu (Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University)
Dayem, Ahmed Abdal (Department of Stem Cell and Regenerative Biotechnology, Konkuk University)
Lim, Kyung Min (Department of Stem Cell and Regenerative Biotechnology, Konkuk University)
Kim, Se Jong (Department of Stem Cell and Regenerative Biotechnology, Konkuk University)
An, Jong Yub (Department of Stem Cell and Regenerative Biotechnology, Konkuk University)
Lee, Yoonjoo (Department of Stem Cell and Regenerative Biotechnology, Konkuk University)
Choi, Yujin (Department of Stem Cell and Regenerative Biotechnology, Konkuk University)
Kirubhakaran, Arthi (Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University)
Cho, Ssang-Goo (Department of Stem Cell and Regenerative Biotechnology, Konkuk University)
Vellingiri, Balachandar (Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University)
Publication Information
BMB Reports / v.53, no.8, 2020 , pp. 400-412 More about this Journal
Abstract
The world has witnessed unimaginable damage from the coronavirus disease-19 (COVID-19) pandemic. Because the pandemic is growing rapidly, it is important to consider diverse treatment options to effectively treat people worldwide. Since the immune system is at the hub of the infection, it is essential to regulate the dynamic balance in order to prevent the overexaggerated immune responses that subsequently result in multiorgan damage. The use of stem cells as treatment options has gained tremendous momentum in the past decade. The revolutionary measures in science have brought to the world mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exo) as therapeutic opportunities for various diseases. The MSCs and MSC-Exos have immunomodulatory functions; they can be used as therapy to strike a balance in the immune cells of patients with COVID-19. In this review, we discuss the basics of the cytokine storm in COVID-19, MSCs, and MSC-derived exosomes and the potential and stem-cell-based ongoing clinical trials for COVID-19.
Keywords
COVID-19; Exosome; Immunomodulation; Mesenchymal stem cells (MSCs); Ongoing Clinical trials; Therapy;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Fan Y, Herr F, Vernochet A, Mennesson B, Oberlin E and Durrbach A (2019) Human fetal liver mesenchymal stem cell-derived exosome impair natural killer cell function. Stem Cells Dev 28, 44-55   DOI
2 Clinicaltrials.gov. Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19. ClinicalTrials. gov Identifier: NCT04366323. https://clinicaltrials.gov/ct2/show/NCT04366323. Accessed on 16th July 2020
3 Clinicaltrials.gov. A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. ClinicalTrials.gov Identifier: NCT04349631. https://clinicaltrials.gov/ct2/show/NCT04349631. Accessed on 16th July 2020
4 Clinicaltrials.gov. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19. Clinical-Trials.gov Identifier: NCT04252118. https://clinicaltrials.gov/ct2/show/NCT04252118. Accessed on 16th July 2020
5 Clinicaltrials.gov. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) ClinicalTrials.gov Identifier: NCT04288102 https://clinicaltrials.gov/ct2/show/NCT04288102?term=Treatment+With+Mesenchymal+Stem+Cells++for+Severe+Corona+Virus+Disease+2019+%28COVID-19%29&draw=2&rank=1. Accessed on 16th July 2020
6 Clinicaltrials.gov. Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) ClinicalTrials.gov Identifier: NCT04346368. https://clinicaltrials.gov/ct2/show/NCT04346368. Accessed on 16th July 2020
7 Domenis R, Cifu A, Quaglia S et al (2018) Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes. Sci Rep 8, 13325   DOI
8 Song Y, Dou H, Li X et al (2017) Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-$1{\beta}$-primed mesenchymal stem cells against sepsis. Stem Cells 35, 1208-1221   DOI
9 Chen W, Huang Y, Han J et al (2016) Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol Res 64, 831-840   DOI
10 Ji L, Bao L, Gu Z et al (2019) Comparison of immunomodulatory properties of exosomes derived from bone marrow mesenchymal stem cells and dental pulp stem cells. Immunol Res 67, 432-442   DOI
11 Wang W, He J and Wu S (2020) The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. doi: https://doi.org/10.1101/2020.02.26.20026989
12 Tufan A, Guler AA and Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50, 620-632   DOI
13 Sakaguchi S, Miyara M, Costantino CM and Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10, 490-500   DOI
14 Zbinden-Foncea H, Francaux M, Deldicque L and Hawley JA (2020) Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity. doi: 10.1002/oby.22849
15 Clinicaltrials.gov. Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019. ClinicalTrials.gov Identifier: NCT04371601.https://clinicaltrials.gov/ct2/show/NCT04371601. Accessed on 26th June 2020
16 Clinicaltrials.gov. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19. ClinicalTrials.gov Identifier: NCT04273646. https://clinicaltrials.gov/ct2/show/NCT04273646. Accessed on 16th July 2020
17 Clinicaltrials.gov. Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia. ClinicalTrials.gov Identifier: NCT04339660. https://clinicaltrials.gov/ct2/show/NCT04339660. Accessed on 16th July 2020
18 Clinicaltrials.gov. Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome. ClinicalTrials.gov Identifier: NCT04366063. https://clinicaltrials.gov/ct2/show/NCT04366063. Accessed on 16th July 2020
19 Clinicaltrials.gov. Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19. ClinicalTrials.gov Identifier: NCT04349540. https://clinicaltrials.gov/ct2/show/NCT04349540. Accessed on 16th July 2020
20 Clinicaltrials.gov. Use of UC-MSCs for COVID-19 Patients. ClinicalTrials.gov Identifier: NCT04355728. https://clinicaltrials.gov/ct2/show/NCT04355728. Accessed on 16th July 2020
21 Clinicaltrials.gov. Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19. ClinicalTrials. gov Identifier: NCT04362189. https://clinicaltrials.gov/ct2/show/NCT04362189. Accessed on 26th June 2020
22 Clinicaltrials.gov. Treatment of COVID-19 patients using Wharton's Jelly- Mesenchymal Stem Cells. ClinicalTrials. gov Identifier: NCT04313322. https://clinicaltrials.gov/ct2/show/NCT04313322. Accessed on 16th July 2020
23 Mardpour S, Hamidieh AA, Taleahmad S, Sharifzad F, Taghikhani A and Baharvand H (2019) Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content. J Cellular Physiol 234, 8249-8258   DOI
24 Clinicaltrials.gov. Safety and Efficacy study of Allogenic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients. ClinicalTrials.gov Identifier: NCT04336254. https://clinicaltrials.gov/ct2/show/NCT04336254. Accessed on 16th July 2020. Accessed on 16th July 2020
25 Clinicaltrials.gov. NestCell Mesenchymal Stem Cells to Treat Patients with Severe COVID-19 Pneumonia. ClinicalTrials. gov Identifier: NCT04315987. https://clinicaltrials.gov/ct2/show/NCT04315987.Accessed on 16th July 2020
26 Clinicaltrials.gov. Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells. ClinicalTrials.gov Identifier: NCT04302519. https://clinicaltrials.gov/ct2/show/NCT04302519. Accessed on 26th June 2020
27 Clinicaltrials.gov. Treatment of Covid-19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells. ClinicalTrials.gov Identifier: NCT04382547. https://clinicaltrials.gov/ct2/show/NCT04382547. Accessed on 26th June 2020
28 He Ping (2019) AB0291E the effect of human umbilical cord mesenchymal stem cells-derived exosomes on chemokines in collagen-induced arthritis rats. BMJ 1606-1606
29 Baharlooi H, Azimi M, Salehi Z and Izad M (2020) Mesenchymal stem cell-derived exosomes: A Promising therapeutic ace card to address autoimmune diseases. Int J Stem Cells 13, 13-23   DOI
30 Du Y, Zhuansun Y, Chen R, Lin L, Lin Y and Li J (2018) Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma. Exp Cell Res 363, 114-120   DOI
31 Clinicaltrials.gov. Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19. ClinicalTrials.gov Identifier: NCT04390152. https://clinicaltrials.gov/ct2/show/NCT04390152. Accessed on 16th July 2020
32 Clinicaltrials.gov. Treatment With Human Umbilical Cordderived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19). ClinicalTrials.gov Identifier: NCT04288102. https://clinicaltrials.gov/ct2/show/NCT04288102. Accessed on 16th July 2020
33 Clinicaltrials.gov. Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients. ClinicalTrials. gov Identifier: NCT04437823. https://clinicaltrials.gov/ct2/show/NCT04437823. Accessed on 16th July 2020
34 Clinicaltrials.gov. Clinical Use of Stem Cells for the Treatment of Covid-19. ClinicalTrials.gov Identifier: NCT 04392778. https://clinicaltrials.gov/ct2/show/NCT04392778. Accessed on 16th July 2020
35 Khatri M, Richardson LA and Meulia T (2018) Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther 9, 17   DOI
36 Fujita Y, Kosaka N, Araya J, Kuwano K and Ochiya T (2015) Extracellular vesicles in lung microenvironment and pathogenesis. Trends Mol Med 21, 533-542   DOI
37 Barani B, Rajasingh S and Rajasingh J (2017) Exosomes: Outlook for future cell-free cardiovascular disease therapy. Adv Exp Med Biol 2017, 285-307
38 Tsuji K, Kitamura S and Wada J (2018) Secretomes from mesenchymal stem cells against acute kidney injury: possible heterogeneity. Stem Cells Int 2018, 8693137   DOI
39 Clinicaltrials.gov. MSCs in COVID-19 ARDS .Clinical Trials.gov Identifier: NCT04371393 https://clinicaltrials.gov/ct2/show/NCT04371393. Accessed on 16th July 2020
40 Clinicaltrials.gov. Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 (COVIDMES). ClinicalTrials.gov Identifier: NCT04390139. https://clinicaltrials.gov/ct2/show/NCT04390139. Accessed on 16th July 2020
41 Chen J, Hu C, Chen L et al (2020) Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering. https://doi.org/10.1016/j.eng.2020.02.006
42 Vikram S, Sascha S, Angel L et al (2020) Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 29, 747-754   DOI
43 Leng Z, Zhu R, Hou W et al (2020) Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11, 216-228   DOI
44 Clinicaltrials.gov. $NestaCell^{(R)}$ Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE). ClinicalTrials.gov Identifier: NCT04315987. https://clinicaltrials.gov/ct2/show/NCT04315987. Accessed on 16th July 2020
45 Clinicaltrials.gov. Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard (CIRCA-19). ClinicalTrials.gov Identifier: NCT04400032. https://clinicaltrials.gov/ct2/show/NCT04400032. Accessed on 16th July 2020
46 Clinicaltrials.gov. ACT-20 in Patients With Severe COVID-19 Pneumonia. ClinicalTrials.gov Identifier: NCT04398303. https://clinicaltrials.gov/ct2/show/NCT04398303. Accessed on 16th July 2020
47 Clinicaltrials.gov. Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19). ClinicalTrials.gov Identifier: NCT04416139. https://clinicaltrials.gov/ct2/show/NCT04416139. Accessed on 16th July 2020
48 Kim K, Gil M, Dayem AA et al (2020) Improved isolation and culture of urine-derived stem cells (USCs) and enhanced production of immune cells from the USC-derived induced pluripotent stem cells. J Clin Med 9, 827   DOI
49 Kim K, Abdal Dayem A, Gil M et al (2020) 3,2'- Dihydroxyflavone Improves the proliferation and survival of human pluripotent stem cells and their differentiation into hematopoietic progenitor cells. J Clin Med 9, 669   DOI
50 Clinicaltrials.gov. Cell Therapy Using Umbilical Cordderived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (STROMA-CoV2) ClinicalTrials.gov Identifier: NCT04333368. https://clinicaltrials.gov/ct2/show/NCT04333368?term=Wharton&results?cond=COVIDcovid-19&draw=2&rank=2.term=stem+cell&cntry=&state=&city=&dist=. Accessed on 26th June 2020
51 Clinicaltrials.gov. Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19. ClinicalTrials.gov Identifier: NCT04428801. https://clinicaltrials.gov/ct2/show/NCT04428801. Accessed on 26th June 2020
52 Clinicaltrials.gov. A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia. ClinicalTrials.gov Identifier: NCT04276987.https://clinicaltrials.gov/ct2/show/NCT04276987. Accessed on 26th June 2020. Accessed on 26th June 2020
53 Patel SA, Meyer JR, Greco SJ, Corcoran KE and Bryan M, Rameshwar P (2010) Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-${\beta}$. J Immunol 184, 5885-5894   DOI
54 Muraca M, Pessina A, Pozzobon M et al (2020) Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?. J Control Release 325, 135-140   DOI
55 Tsuchiya A, Takeuchi S, Iwasawa T et al (2020) Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Inflammation and Regeneration 40, 1-6   DOI
56 Akkoc T (2020) COVID-19 and mesenchymal stem cell treatment; mystery or not. Adv Exp Med Biol. 1-10 https://doi.org/10.1007/5584_2020_557
57 Raffaghello L, Bianchi G, Bertolotto M et al (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26, 151-162   DOI
58 Thanunchai M, Hongeng S and Thitithanyanont A (2015) Mesenchymal stromal cells and viral infection. Stem Cells Int 2015, 860950
59 Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML and Corsico AG (2020) Mesenchymal stromal cell secretome for severe COVID-19 infections: Premises for the therapeutic use. Cells 9, 924   DOI
60 Pinky, Gupta S, Krishnakumar V et al (2020) Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19. Stem Cell Rev Rep 1-11 doi: 10.1007/s12015-020-10002-z
61 O'Driscoll L (2020) Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment. Drug Discovery Today. S1359-6446(20)30170-7. https://doi.org/10.1016/j.drudis.2020.04.022
62 Sleem A and Saleh F (2020) Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy. Curr Res Transl Med S2452-3186(20)30031-3. doi: 10.1016/j.retram.2020.04.003
63 Harrell CR, Jovicic N, Djonov V et al (2020) Therapeutic Use of Mesenchymal Stem Cell-Derived Exosomes: From Basic Science to Clinics. Pharmaceutics 12, 474   DOI
64 Balachandar V, Mahalaxmi I, Kaavya J et al (2020) COVID-19: emerging protective measures. Eur Rev Med Pharmacol Sci 24, 3422-3425
65 Clinicaltrials.gov. A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy. ClinicalTrials.gov Identifier: NCT04445220 https://clinicaltrials.gov/ct2/show/NCT04445220. Accessed on 16th July 2020
66 Lou G, Chen Z, Zheng M and Liu Y (2017) Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med 49, e346-e346   DOI
67 Crivelli B, Chlapanidas T, Perteghella S et al (2017) Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J Controlled Release 262, 104-117   DOI
68 Deffune E, Prudenciatti A and Moroz A (2020) Mesenchymal stem cell (MSc) secretome: a possible therapeutic strategy for intensive-care COVID-19 patients. Med Hypotheses 142, 109769   DOI
69 Keshtkar S, Azarpira N and Ghahremani MH (2018) Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther 9, 63   DOI
70 Lai P, Chen X, Guo L et al (2018) A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol 11, 135   DOI
71 Alvarez V, Sanchez-Margallo FM, Macias-Garcia B et al (2018) The immunomodulatory activity of extracellular vesicles derived from endometrial mesenchymal stem cells on CD4+ T cells is partially mediated by TGFbeta. J Tissue Eng Regen Med 12, 2088-2098
72 Clinicaltrials.gov. Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS Clinical-Trials.gov Identifier: NCT04331613. https://clinicaltrials.gov/ct2/show/NCT04331613. Accessed on 16th July 2020
73 Clinicaltrials.gov. Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation Clinical-Trials.gov Identifier: NCT04397796. https://clinicaltrials.gov/ct2/show/NCT04397796. Accessed on 16th July 2020
74 Shneider A, Kudriavtsev A and Vakhrusheva A (2020) Can melatonin reduce the severity of COVID-19 pandemic? Int Rev Immunol 39, 153-162   DOI
75 Guo J, Huang Z, Lin L and Lv J (2020) Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 9, e016219
76 Clinicaltrials.gov. Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19ClinicalTrials.gov Identifier: NCT04389450. https://clinicaltrials.gov/ct2/show/NCT04389450. Accessed on 16th July 2020
77 Clinicaltrials.gov. Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19. ClinicalTrials.gov Identifier: NCT04299152 https://clinicaltrials.gov/ct2/show/NCT04299152.Accessed on 16th July 2020
78 Clinicaltrials.gov. Therapy for Pneumonia Patients Infected by 2019 Novel Coronavirus ClinicalTrials.gov Identifier: NCT04293692. https://clinicaltrials.gov/ct2/show/NCT04293692. Accessed on 16th July 2020
79 Clinicaltrials.gov. Battle Against COVID-19 Using Mesenchymal Stromal Cells. ClinicalTrials.gov Identifier: NCT04348461. https://clinicaltrials.gov/ct2/show/NCT04348461. Accessed on 16th July 2020
80 Clinicaltrials.gov. ASC Therapy for Patients With Severe Respiratory COVID-19. ClinicalTrials.gov Identifier: NCT04341610. https://clinicaltrials.gov/ct2/show/NCT04341610. Accessed on 16th July 2020
81 Clinicaltrials.gov. Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS). ClinicalTrials.gov Identifier: NCT04377334. https://clinicaltrials.gov/ct2/show/NCT04377334. Accessed on 16th July 2020
82 Wilson JG, Liu KD, Zhuo H et al (2015) Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3, 24-32   DOI
83 Conti P, Ronconi G, Caraffa A et al (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34, 1
84 Zhao Q, Ren H and Han Z (2016) Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother 2, 3-20   DOI
85 Prockop DJ (2017) The exciting prospects of new therapies with mesenchymal stromal cells. Cytotherapy 19, 1-8   DOI
86 Uccelli A, Moretta L and Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8, 726-736   DOI
87 Ren G, Zhang L, Zhao X et al (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150   DOI
88 Waterman RS, Tomchuck SL, Henkle SL and Betancourt AM (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5, e10088   DOI
89 Vellingiri B, Jayaramayya K, Iyer M et al (2020) COVID-19: A promising cure for the global panic. Sci Total Environ 725, 138277   DOI
90 Grasselli G, Zangrillo A, Zanella A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323, 1574-1581   DOI
91 Sun X, Wang T, Cai D et al (2020) Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2020.04.002
92 Clinicaltrials.gov. Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease). ClinicalTrials.gov Identifier: NCT04345601. https://clinicaltrials.gov/ct2/show/NCT04345601. Accessed on 16th July 2020
93 Clinicaltrials.gov. Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia. ClinicalTrials.gov Identifier: NCT04269525. https://clinicaltrials.gov/ct2/show/NCT04269525. Accessed on 16th July 2020
94 Clinicaltrials.gov. MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) ClinicalTrials.gov Identifier: NCT04367077. https://clinicaltrials.gov/ct2/show/NCT04367077. Accessed on 16th July 2020
95 Clinicaltrials.gov. Treatment of Severe COVID-19 Pneumonia with Allogeneic Mesenchymal Stromal Cells (COVID_MSV) Clinical Trials.gov Identifier: NCT04361942. https://clinicaltrials.gov/ct2/show/NCT04361942. Accessed on 16th July 2020
96 Clinicaltrials.gov. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)ClinicalTrials.gov Identifier: NCT03042143. https://clinicaltrials.gov/ct2/show/NCT03042143. Accessed on 16th July 2020
97 Clinicaltrials.gov. Mesenchymal Stem Cell Infusion for COVID-19 Infection. ClinicalTrials.gov Identifier: NCT04444271. https://clinicaltrials.gov/ct2/show/NCT04444271. Accessed on 16th July 2020
98 Clinicaltrials.gov. Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia (CELMA). ClinicalTrials.gov Identifier: NCT04429763. https://clinicaltrials.gov/ct2/show/NCT04429763. Accessed on 16th July 2020
99 Taghavi-farahabadi, M, Mahmoudi M, Soudi S and Hashemi SM (2020) Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cellderived exosomes. Med Hypotheses 144, 109865   DOI
100 Balachandar V, Mahalaxmi I, Devi SM et al (2020) Follow-up studies in COVID-19 recovered patients-is it mandatory? Sci Total Environ 729, 139021   DOI
101 Li G, Fan Y, Lai Y et al (2020) Coronavirus infections and immune responses. J Med Virol 92, 424-432   DOI
102 Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. doi: 10.1093/cid/ciaa248
103 Iyer M, Jayaramayya K, Subramaniam MD et al (2020) COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep 53, 191-205   DOI
104 Clinicaltrials.gov. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. ClinicalTrials.gov Identifier: NCT04348435. https://clinicaltrials.gov/ct2/show/NCT04348435. Accessed on 16th July 2020